Mp53-12 Predictive Roles of Nets and Igg in Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

You have accessJournal of UrologyBladder Cancer: Invasive V (MP53)1 May 2024MP53-12 PREDICTIVE ROLES OF NETS AND IGG IN NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER Bingqing Shang, Ruiyang Xie, Honglei Cui, Zhaoru Gu, Jie Wu, Aiping Zhou, Hongzhe Shi, and Jianzhong Shou Bingqing ShangBingqing Shang , Ruiyang XieRuiyang Xie , Honglei CuiHonglei Cui , Zhaoru GuZhaoru Gu , Jie WuJie Wu , Aiping ZhouAiping Zhou , Hongzhe ShiHongzhe Shi , and Jianzhong ShouJianzhong Shou View All Author Informationhttps://doi.org/10.1097/01.JU.0001008784.37684.bd.12AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Cisplatin-based chemotherapy is the recommended therapy for muscle-invasive bladder cancer (MIBC), in the neoadjuvant setting. However, the efficacy of MIBC for chemotherapy is only about 40%. Therefore, predictors of therapy response are urgently needed. Neutrophils form neutrophil extracellular traps (NETs), a network structure, and growing evidence indicated that it could be a prognostic and predictive marker in cancer. Besides, NETs and IgG could reflect the immune response, even may induce immune tolerance. In MIBC, the predictive role of NETs or IgG in chemotherapy resistance is unclear. METHODS: This study included 54 patients with MIBC undergoing neoadjuvant chemotherapy. Immunohistochemical staining with NETs was performed on tumor primary lesions before chemotherapy, and the staining intensity was scored. Serum IgG levels in the pre-treatment baseline and 1 month after chemotherapy were also measured for these patients. RESULTS: Citrullinated histone H3 (H3Cit) as a hallmark of NETs, was an independent predictor of chemotherapy resistance as determined by the multivariate logistic regression analyses OR=5.94, 95% CI 1.20–45.50, p=0.045. Additionally, in patients with favorable chemotherapy response, serum IgG levels significantly decreased after 1 month of treatment (p=0.0018), while in those with poor response, there was no significant change. CONCLUSIONS: The baseline levels of NETs and the change of IgG after 1-month treatment demonstrated predictive capabilities during neoadjuvant chemotherapy, possibly reflecting the immune status. MIBC patients with high NETs and IgG levels were resistant to neoadjuvant chemotherapy, providing new insights into the treatment of MIBC. However, these results require further validation through larger sample studies. Further validation of our findings could provide a theoretical basis regarding NETs inhibitors or IgG antibodies combined with chemotherapy strategy. Source of Funding: This work was supported by the National Natural Science Foundation of China (ID Number: 82072837). This study was also funded by Beijing Municipal Natural Science Foundation (ID Number: 7212083) and CAMS Initiative for Innovative Medicine (CAMS-I2M) 2016-I2M-1-007 © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e867 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Bingqing Shang More articles by this author Ruiyang Xie More articles by this author Honglei Cui More articles by this author Zhaoru Gu More articles by this author Jie Wu More articles by this author Aiping Zhou More articles by this author Hongzhe Shi More articles by this author Jianzhong Shou More articles by this author Expand All Advertisement PDF downloadLoading ...